New drug cocktail shows promise for Hard-to-Treat lymphomas
NCT ID NCT05371054
First seen Dec 12, 2025 · Last updated Apr 24, 2026 · Updated 16 times
Summary
This study tested a new combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive blood cancers like diffuse large B-cell lymphoma that had returned or not responded to prior treatments. The goal was to find a safe dose and see if the combination could shrink tumors. Participants took pills at home and received one drug through an IV at the clinic. The study is now complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.